THDBH110
/ Tonghua Dongbao, WuXi AppTec
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 28, 2023
Tonghua Dongbao’s net profit fell by 59% in the first half of the year, and the layout of weight-loss drugs has “many opponents” [Google translation]
(XINHUANET.com)
- "Tonghua Dongbao also announced the acceptance notice of clinical trial application for its oral small molecule GLP-1 receptor agonist (THDBH110 capsule)....THDBH110 capsule, as an oral non-peptide, small molecule GLP-1 receptor agonist, will provide a new option for patients with type II diabetes and obesity in terms of reducing blood sugar, weight and cardiovascular risk, and improve Patient medication convenience and compliance."
New trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1